Repligen: A Strong Investment For The Right Kind Of Investor
- Employing a business model from generations past makes Repligen a stable and sturdy investment option for old-school investors.
- Focusing on the supply-chain end of the biopharmaceutical commercialization process, Repligen offers an investment into the space which is comparably more protected against downside risk.
- In focusing on bioprocessing as its principal business since 2012, Repligen has become leaner, meaner, and more productive for shareholders.
- While steady growth appears nearly inevitable over time, potential investors must be capable of employing both patience and a disciplined approach to building their position.